VVN461 clinical trials
How each study uses VVN461 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
VivaVision Biotech, Inc (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test VVN461, phase 3 first.
- Dec 2026A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisPhase 3 · VivaVision Biotech, Inc
Studies
Open first, then newest update. How each study uses VVN461 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract SurgeryCompletedPhase 2VivaVision Biotech, IncNCT06164743Written as VVN461 Ophthalmic Solution 1.0%
- A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisActive, not recruitingPhase 3VivaVision Biotech, IncNCT07136805Written as VVN461 Ophthalmic Solution 1.0%
- Pharmacokinetics of VVN461 Ophthalmic SolutionCompletedPhase 1VivaVision Biotech, IncNCT06906198Written as VVN461 Ophthalmic Solution 1.0%
- A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisCompletedPhase 2VivaVision Biotech, IncNCT06679153Written as VVN461 Ophthalmic Solution 1.0%